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Abstract: The purpose of this study was to identify and characterize fungal natural 
products (NPs) with in vitro bioactivity towards leukemia cells. We based our screening on 
a combined analytical and bio-guided approach of LC-DAD-HRMS dereplication, 
explorative solid-phase extraction (E-SPE), and a co-culture platform of CLL and stromal 
cells. A total of 289 fungal extracts were screened and we tracked the activity to single 
compounds in seven of the most active extracts. The novel ophiobolin U was isolated 
together with the known ophiobolins C, H, K as well as 6-epiophiobolins G, K and N from 
three fungal strains in the Aspergillus section Usti. Ophiobolins A, B, C and K displayed 
bioactivity towards leukemia cells with induction of apoptosis at nanomolar concentrations. 
The remaining ophiobolins were mainly inactive or only slightly active at micromolar 
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concentrations. Dereplication of those ophiobolin derivatives possessing different activity 
in combination with structural analysis allowed a correlation of the chemical structure and 
conformation with the extent of bioactivity, identifying the hydroxy group at C3 and an 
aldehyde at C21, as well as the A/B-cis ring structure, as indispensible for the strong 
activity of the ophiobolins. The known compounds penicillic acid, viridicatumtoxin, 
calbistrin A, brefeldin A, emestrin A, and neosolaniol monoacetate were identified from 
the extracts and also found generally cytotoxic. 
Keywords: natural products; ophiobolin U; dereplication; explorative solid phase 
extraction (E-SPE); filamentous fungi; cytotoxic; cancer; leukemia 
 
1. Introduction 
Screening and discovery of compounds that act against chronic lymphocytic leukemia (CLL) cells 
are crucial since CLL is considered as an incurable disease and currently applied treatment strategies 
primarily aim at prolonging patient survival [1,2]. Filamentous fungi have proven to be an incredible 
source of diverse bioactive compounds. The continuous improvements of analytical instruments and 
new approaches for fast dereplication have resulted in an increased interest in natural products 
discovery [3–5]. CLL is the most common type of leukemia among adults in the Western World. Even 
though most patients initially show a good response to therapy, relapse of disease is very frequent, 
with a subsequent increase in chemoresistance [6]. Consequently, there is a great need for discovery 
and development of new agents. Treatment strategies used today are based on small-molecule 
alkylating agents such as chlorambucil and fludarabine. These agents are often used in combination 
with monoclonal antibodies, or more recently inhibitors that target essential signaling pathways in 
CLL [7,8]. In contrast to other cancer cells, the majority of CLL cells is non-proliferating, arrested in 
G0/G1 phase of the cell cycle and accumulates in the patients due to apoptosis resistance [1]. In vivo, 
CLL cells are associated with a survival-inducing microenvironment of stromal cells, non-malignant 
leukocytes, so-called nurse-like cells, as well as growth and differentiation factors [9,10]. Removed 
from their natural microenvironment, the CLL cells rapidly undergo apoptosis in vitro, even though 
they are long-living cells in vivo [11]. However, viability of CLL cells can be maintained in vitro by 
co-cultivation with stromal cells, for example the bone marrow-derived cell line HS-5 [12,13]. Such 
co-cultures mimic the microenvironment of CLL cells in vivo, they are ideally suited for screening of 
natural products (NPs) [14]. We have already demonstrated that fungal NPs are a proper source for 
discovering compounds with activity towards CLL cells in vitro. This was done by identification of 
chaetoglobosin A from P. aquamarinum. Chaetoglobosin A induced apoptosis in CLL cells more 
selectively compared to healthy cells with a median lethal dose (LC50) of 2.8 µM [15]. 
Novel secondary metabolites produced by filamentous fungi such as Penicillium and Aspergillus 
are being discovered continuously [4,16]. With the increase in target-based specific biological assays, 
previously described compounds might display novel bioactivities [17,18], justifying their presence in 
novel screening efforts. Testing all known as well as novel NPs against all disease targets is an 
impracticable approach, why setting up a suitable strategy is essential to any screening program [19]. 
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Targeted screening strategies in NPs-based drug discovery rely on identifying compounds targeting a 
specific disease or biological mechanism. In such screening campaigns, the selection of fungi is 
essential and needs to represent as wide a biodiversity as possible, with the hope of an equally high 
chemodiversity [19]. One strategy to increase chemodiversity for rapid bio-testing is to select strains 
representing a wide variety of species with a limited number of strains from each species [19,20]. The 
spectrum of compounds produced by the individual strains can further be diversified or maximized by 
the ‘one strain-many compounds’ (OSMAC) approach, through variation of culture conditions [16]. 
Dereplication is the tentative identification of known NPs in complex mixtures, before unnecessary 
time is spent on isolating already known compounds. One dereplication approach is based on liquid 
chromatography-diode array detection-high resolution mass spectrometry (LC-DAD-HRMS) and 
database searching, which ensures a high throughput and reproducibility [3]. Subsequent to 
dereplication a separation strategy for preparative isolation of NPs is necessary. Here a small scale 
preliminary chemical characterization focusing on identification of functional groups is helpful.  
Co-eluting interferences often experienced in traditional reverse phase (RP) chromatography can be 
reduced or even completely removed by choosing orthogonal purifications strategies [21]. One 
approach for prefractionation is explorative solid-phase-extraction (E-SPE) [21] that relies on  
ion-exchanger columns such as strong anion-exchanger (SAX), mixed mode anion-exchanger (MAX), 
and strong cation-exchanger (SCX). This method has proven to be very powerful for separating fungal 
NPs due to the relative high percentages of ionizable functional groups [21].  
In this current paper we describe our screening efforts of discovering fungal NPs with bio-activity 
in a co-culture platform of chronic lymphocytic leukemia (CLL) cells and stromal cells and their 
retesting in CLL cells cultures in conditioned media of stromal cells [12]. The fungal NPs were 
tentatively identified by LC-DAD-HRMS based dereplication and extracts were fractionated in order 
to assign the activity to single compounds [3]. Confidence in this identification was improved by using 
an E-SPE strategy based on an array of orthogonal separation techniques [19,21]. Thereby among 
others, ophiobolins were identified and further structural studies were performed by dereplicating 
different ophiobolin dervatives leading to the identification of chemical moieties and conformations 
that are indispensable for strong bioactivity. Ophiobolins lacking these moieties possessed either low 
or no bioactivity. 
2. Results and Discussion 
A total of 289 fungal extracts were prepared from cultivation of 137 fungal strains (Figure 1 and 
Table S1) on a selection of solid media at variable temperatures in accordance with the OSMAC 
approach [16]. The extracts were prepared by the micro-extraction method developed by  
Smedsgaard [22]. To obtain a representative sample of the fungal colonies the plugs were taken across 
the colony. Sixty one (61) extracts showed activity towards CLL cells (Table S2). Seven of the 
candidates that displayed the highest level of activity (Figure 1) were selected for further bio-testing. 
Large-scale extracts were prepared from incubation on the media supporting the highest level of 
bioactivity, and the extracts were prefractionated before further testing. 
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Figure 1. Screening set-up. Two hundred and eighty nine (289) fungal extracts (from 137 
fungal strains) were tested for cell death-inducing activity for CLL cells but not for stromal 
cells. From the 61 active extracts the seven candidates that displayed the highest bio-assay 
activity were selected for single compound isolation in a large scale and further bio testing. 
 
2.1. MS Based Dereplication of Penicillium pulvillorum Extract 
The extract of P. pulvillorum (IBT 22393) was among the candidates that displayed the highest 
level of activity (≈1.25 µg/mL). The first five flash fractions (ranging from 15%–40% organic) were 
tested active against CLL cells in vitro. LC-DAD-HRMS revealed one major component shared 
between these fractions, with an elementary composition of C8H10O4 (−0.7 ppm mass accuracy) (Figure 2). 
AntiBase2012 [23] revealed penicillic acid as a likely candidate responsible for the observed activity. 
The tentative identification of penicillic acid was confirmed by comparison of the retention time to a 
standard from our in-house metabolite database (1,559 standards) as well as comparison of 1H- and  
13C-NMR chemical shifts to the literature data [24]. 
Figure 2. Dereplication of penicillic acid from P. pulvillorum mass spectrum of penicillic 
acid [23]. The mass spectrum shows a widespread adduct pattern that besides [M+H]+ 
contains ions that corresponds to neutral loss of water [M+H-H2O]+ and the sodiated 
adduct [M+Na]+, as well as the corresponding dimeric ions [2M+H]+, [2M+H-H2O]+,  
and [2M+Na]+. 
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To verify the observed anti-leukemic activity in the extract, penicillic acid was purified and tested 
on CLL cells, resulting in induced cell death in both CLL and stromal (HS-5) cells. No further work on 
this extract was done as penicillic acid is regarded as a generally cytotoxic compound [24]. 
2.2. Comparative Dereplication Based on Explorative Solid Phase Extraction (E-SPE) 
The E-SPE strategy was applied to a series of highly complex extracts, i.e., P. brasilianum  
(IBT 22244), P. decumbens (IBT 11843), P. cluniae (IBT 21051), Aspergillus sp. (Emericella-like state) 
(IBT 22838), and Fusarium compactum (IBT 9034). The extract of P. brasilianum (IBT 22244) was 
very potent against CLL cells in vitro (≈5 ng/mL) with the active compound retained on both anion-
exchangers (SAX and MAX) as well as the two normal-phase columns (diol and amino), while 
unretained on the cation-exchanger (SCX). The combined biological and chromatographic information 
lead to the conclusion that the bioactive compound contained a strong anion. The large scale extract 
was fractionated on a SAX column. Comparison of chromatographic peaks from the fraction that 
contained neutral/basic compounds (Figure 3a) and the fraction with acidic compounds (Figure 3b), 
showed that the anion-exchange was extremely selective, removing the majority of inactive 
compounds from the extract. 
Figure 3. E-SPE strategy based on a SAX column to separate co-eluting compounds in the 
crude extract of P. brasilianum. (a) UHPLC chromatograms of the SAX fraction that 
contained neutral/basic compounds. The ion trace of compound I (m/z 462.2387) is marked 
with red; (b) UHPLC chromatogram of the SAX fraction that contained acidic compounds. 
The ion trace of compound IV (m/z 548.1916) is marked with blue; (c) In the crude extract 
compound I and IV were co-eluting on a RP C18 column. 
 
In the initial extract, the two compounds I and IV co-eluted on a C18 RP column (Figure 3c). These 
were easily and quantitatively separated on the SAX column due to the difference in charged 
functionalities. Only three major acidic compounds were left in the bioactive fraction (Figures 3b and 4a), 
significantly simplifying the subsequent dereplication and purification process. Based on comparative 
HRMS analysis, compound II was immediately eliminated due to its presence in the inactive 
neutral/basic fraction. The molecular formula of compounds III and IV were established as C15H10O9 
(−0.7 ppm) and C30H31NO10 (−0.2 ppm), respectively. These were used as queries in AntiBase2012 
(Figure 4b) [23]. Compound II had no hits in AntiBase2012 that contained a strong anion, thus likely 
being a novel compound or novel analogue of a known compound. Compound IV had two hits in 
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AntiBase2012. One of the candidates had no strong anion and was consequently eliminated, which left 
viridicatumtoxin as the only candidate (Figure 4b). 
Figure 4. Dereplication of the P. brasilianum extract (a) UHPLC chromatogram of the 
active SAX fraction that contained the acidic compounds as well as UV and MS spectra of 
the potential candidates; (b) Hits in Antibase2012. 
(b) 
III: Unknown  IV: Viridicatumtoxin 
Query No. of candidates  Query No. of candidates 
C15H10O9 1  C30H31NO10 2 
Strong anion 0  Strong anion 1 
 
The identity of viridicatumtoxin as compound IV was confirmed: (1) by comparison to the retention 
time and UV spectrum of an in-house standard; (2) by the fact that it held a strong anion; and (3) by 
having similar 1H-NMR chemical shifts as published for viridicatumtoxin [25]. Viridicatumtoxin was 
isolated as one of the most cytotoxic compounds tested towards CLL cells in this screening campaign 
with a median lethal concentrations (LC50) value between 0.7 and 3.5 nM. Further testing revealed that 
the activity was not specific, as both CLL and stromal cells were targeted. 
One flash fraction (70% organic) from the P. decumbens (IBT 11843) extract was found active 
towards CLL cells (≈200 ng/mL). Further E-SPE analysis showed that the active compound was 
retained on SAX and MAX columns indicating the presence of a strong anion. By comparative 
dereplication tentative identifications of calbistrin A (Figure 5a) and B as well as their precursor (or 
decomposition product) versiol (Figure 5c) were established within the fraction. The MS based 
dereplication was complicated by the fact that the [M+H]+ ion was absent in the mass spectra of 
calbistrin A and B. The presences of strong adduct- and fragmentation patterns consisting of the 
sodiated, [M+Na]+, and the ammoniated, [M+NH4]+, adducts as well as neutral loss of one and two 
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water molecules assisted the establishment of the monoisotopic masses and hereby the molecular 
formulas of calbistrin A and B. The identity of calbistrin A was confirmed by the presence of a 
carboxylic acid and by comparison of retention time and UV spectrum to an in-house standard. The 
tentative identity of calbistrin B was confirmed by comparison of the UV spectrum to that of calbistrin 
A (Figure 5a). Testing of calbistrin A from our in-house metabolite collection showed general 
cytotoxic activity towards CLL and healthy cells. Comparative experiments with calbistrin C (Figure 5b) 
from the metabolite collection did not induce cell death, indicating that the pharmacophore is located 
in the versiol part (Figure 5c) of the molecule. 
Figure 5. Structure of (a) Calbistrin A, (b) Calbistrin C, and (c) Versiol. 
 
A bioactive flash fraction (activity approx. 100 ng/mL) from a Penicillium cluniae (IBT 21051) 
extract was likewise subjected to E-SPE. Here, the bioactivity profiled revealed that the active 
compound was a medium to apolar compound with no charged functionalities. By comparative 
dereplication, the active compound was tentatively identified as brefeldin A (Figure 6a), which was in 
accordance with the profile revealed by E-SPE. The identity of brefeldin A was confirmed by its 
retention time and UV spectrum compared to an in-house standard. Brefeldin A is a known anticancer 
compound [5,26] and commercially available, thus the activity was easily confirmed in the CLL assay. 
The compound displayed general cytotoxic activity for CLL cells (0.39–1.56 µM) and stromal cells. 
Figure 6. Examples of E-SPE and comparative dereplication (a) Brefeldin produced by  
P. cluniae, (b) Emestrin A produced by Aspergillus sp. (Emericella-like state), and (c) 
Neosolaniol monoacetate produced by F. compactum. 
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The E-SPE strategy of the bioactive extract (≈40 ng/mL) from Aspergillus sp. (Emericella-like 
state, IBT 22838) resulted in retention of the bioactive compound on the amino normal phase SPE 
column. Fast comparative dereplication based on UV spectra and retention times of in-house standards 
as well as comparison of 1H-NMR chemical shifts [27] led to an identification of the known antifungal 
and anticancer compound, emestrin A (Figure 6b) [5,28,29]. The pure emestrin A isolated form the 
active fractions showed cytotoxic activity towards CLL cells and stromal cells at the same concentration 
levels. Accordingly, emestrin A is regarded as a generally cytotoxic compound with no therapeutic 
window [30]. No further work was pursued on the Aspergillus sp. (Emericella-like state) extract. 
The last example of bio-guided isolation based on E-SPE is demonstrated by the F. compactum 
(IBT 9034) extract with an activity at approximately 200 ng/mL. The bioactive compound from  
F. compactum was retained on both the diol and amino columns in the E-SPE pre-fractionation 
experiment. Comparative dereplication revealed only one candidate that might be responsible for the 
activity. The compound was tentatively identified as the known trichothecene, neosolaniol 
monoacetate (Figure 6c). The compound was isolated and the 1H-NMR data was compared to the 
literature for final identification of neosolaniol monoacetate [31]. Neosolaniol monoacetate was tested 
in the CLL assay and found as a generally cytotoxic why no further work was performed on the  
F. compactum extract. The E-SPE approach with the optimized collection of ion-exchangers and 
normal phase SPE columns has turned out to be a good combination to evaluate and follow bioactivity 
of fungal extracts. 
2.3. Biological Structure-Activity Relationship of Ophiobolins 
The bioactive extract from a new species in Aspergillus section Usti (IBT 18591) was more 
selective than the above mentioned active extracts and in consequence selected for more detailed 
investigations. MS- and UV-based dereplication led to the tentative identification of the ophiobolin 
family of compounds. Ophiobolin K and 6-epiophiobolin K (Figure 7) [32] were isolated and 
ophiobolin K was found very potent against CLL cells in vitro. 
The ophiobolins are a family of naturally occurring sesterterpenoids, currently comprising more 
than 35 known analogues [33–37]. They all consist of a C25 skeleton with a dicyclopenta[a,d]cyclooctane 
ring system. Some ophiobolins have an extra ring incorporated, as observed in ophiobolin A and H 
(Figure 7), forming two different types of tetra-cyclic structures [38]. The absolute configuration of 
ophiobolin A and G have been determined by X-ray crystallography [39,40] and the conformations of 
all stereocenters except C6 is expected to be conserved based on the biosynthetic production of ophiobolins 
demonstrated by the first sesterterpene synthase described in 2013 [41]. Ophiobolins exhibit a broad 
spectrum of inhibitory activity against cancer cell lines, including lung cancer A549, breast cancer 
MCF7, colon cancer HT29, melanoma Mel20, leukemia P388 and L1210 cell lines [5,34,35,42–45].  
Further investigations of the anti-leukemic activity and pharmacophore of the ophiobolins in the 
CLL/stromal cell co-culture platform were performed with the purpose of isolating a high number of 
naturally occurring analogs as well as identification of novel analogues. Taking advantage of the huge 
biodiversity available in the IBT culture collection [19], we expanded the biodiversity and hereby the 
expected chemodiversity with 12 closely related Aspergilli from the section Usti (Table S7) [46]. 
Cultures of the 12 new strains were extracted in micro-scale [22] to explore their potential for 
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producing ophiobolins. A. insuetus (IBT 28266) and A. calidoustus (IBT 25726) were identified as 
potent ophiobolin producers with one likely novel and more known ophiobolins analogs compared to 
the original strain (Figure 8). 
The novel ophiobolin U (Figure 9) was isolated together with ophiobolin H [40] (Figure 7) and the 
rare 6-epiophiobolin N [43] (Figure 7) from the A. insuetus extract, while ophiobolin C [47] (Figure 7) 
and 6-epiophiobolin G [43] (Figure 7) were isolated from the A. calidoustus extract. 
The structure of the novel ophiobolin U was elucidated by 1D and 2D NMR spectroscopy. The  
1H-NMR spectrum of ophiobolin U was closely related to that of ophiobolin K with many practically 
identical chemical shifts (Table S8 and S9). The most remarkable difference between ophiobolin U and 
ophiobolin K was found at C5 that shifted 143.9 ppm upfield from 217.0 to 73.1 ppm in the carbon 
spectrum, indicating the disappearance of a ketone group. C5 had an additional HSQC correlation to a 
signal at 4.91 ppm (H5). This significant change indicated a reduction of the ketone (C5) in ophiobolin 
K to a secondary alcohol in ophiobolin U. This reduction was confirmed by the identification of a 
COSY spin system between H1-H2-H6 in ophiobolin K that in ophiobolin U was expanded with a 
vicinal coupling between the protons at 3.02 (H6) and 4.91 (H5) and further a vicinal coupling 
between H5 and the diastereotopic protons at 1.87 (H4a) and 2.68 ppm(H4b) (Figure 10a). 
Figure 7. Structures of ophiobolin A, 3-anhydro-ophiobolin A, 3-anhydro-6-epiophiobolin 
A, ophiobolin B, ophiobolin C, 6-epiophiobolin G, ophiobolin H, 6-epiophiobolin K, 
ophiobolin K, 6-epiophiobolin N, and ophiobolin U. 
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Figure 8. UHPLC chromatograms of (a) the new species in Aspergillus section Usti (IBT 
18591) producing ophiobolin K and 6-epiophiobolin K, (b) A. insuetus (IBT 28266) 
producing the novel ophiobolin U together with ophiobolin H, K, C as well as 6-epiophiobolin 
K and N and (c) A. calidoustus (IBT 25726) producing ophiobolin K and C as well as  
6-epiophiobolin K and G. 
 
Figure 9. Structure of ophiobolin U. 
 
The spin systems identified in the DQF-COSY spectrum of ophiobolin U were assembled through 
HMBC correlations, which also enabled the identification of the quaternary carbon atoms. The most 
important HMBC correlations are shown in Figure 10b. The COSY spin systems were connected by 
HMBC connectivities further confirming the presence of the eight-membered ring. HMBC 
connectivities were found from H5 to the quaternary carbons at 81.9 (C3) and 142.1 ppm (C7), from 
the diastereotopic protons at 1.03 (H1a) and 1.58 ppm (H1b) to C3 and the carbon at 54.0 ppm (C10), 
and finally from H9 to C7 and the quaternary carbon at 44.1 ppm (C11). The reduction at C5 changed 
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the chemical environment of the surrounding carbons (C2, C3, C6, C8 and C21) that were more 
deshielded and therefore shifted 1.8–6.5 ppm downfield compared to ophiobolin K (Table S8). The 
remaining chemical shifts in ophiobolin U matched the chemical shifts of ophiobolin K (Tables S8  
and S9). 
Figure 10. (a) Important DQF-COSY couplings and (b) important HMBC connectivities in 
the novel compound ophiobolin U. 
 
The stereochemistry of the A/B ring system in ophiobolin U (Figure 9) was assigned based on NOE 
correlations and chemical shifts. The A/B-cis ring system was established by the NOE correlations 
found between the protons at 2.30 (H2) and 3.02 ppm (H6), as demonstrated in Figure 11. The 
stereochemistry of C-5 was tentatively assigned through strong NOE correlations of the diastereotopic 
protons at 1.87 (H4a) and 2.68 ppm (H4b). H4a had NOE correlations to the protons at 1.26 ppm 
(H20) and H2, while H4b had a NOE correlation to H5, which indicated that the hydroxy group at C5 
was cis to H6. Other important NOE correlations are shown in Figure 11. 
Figure 11. Important NOE correlations in ophiobolin U. 
 
The A/B-cis was confirmed by chemical shifts. Earlier reports showed that C1 and C22 in 
ophiobolins with A/B-cis ring structure are more upfield compared to ophiobolins with A/B-trans ring 
structure [48]. In ophiobolin U and ophiobolin K, the chemical shifts of C1 and C22 were more upfield 
compared to 6-epiophiobolin K, which indicate a A/B-cis ring structure in ophiobolin U. Other reports 
have showed that the A/B-cis ring structure in ophiobolins causes a small deshielding (0.2–0.3 ppm) 
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for H2 and H8 as well as a small shielding (0.3–0.6 ppm) for H4 [49]. The 1H chemical shifts for 
ophiobolin U were inconclusive regarding conformation of the A/B ring system. The residual 
stereocenters of ophiobolin U were the same as in the known ophiobolins due to the stereospecificity 
of the biosynthetic pathway of the ophiobolins [41,50]. 
The stereochemistry of the A/B ring system of the remaining six ophiobolins (ophiobolin K,  
6-epiophiobolin K, 6-epiophiobolin N, 6-epiophiobolin G, ophiobolin H, and ophiobolin C) isolated in 
this study were confirmed by NOE correlations. Together with the general trend that C1 and C22 in the 
ophiobolins with A/B-cis ring structure were more upfield compared to ophiobolins with A/B-trans 
ring structure [43,48]. The shifting of chemical shifts for H2, H4, and H8 for the A/B-cis ring system 
were more ambiguous due to the small deshielding/shielding in chemical shifts and inconclusive for 
the seven ophiobolins. A comparison of the 13C and 1H chemical shifts of all the seven ophiobolins are 
found in Tables S8 and S9, respectively. 
Besides the seven purified ophiobolins: ophiobolin A, ophiobolin B, 3-anhydroophiobolin A, and  
3-anhydro-6-epiophiobolin A (Figure 7) were bought as standards with the aim of obtaining a broader 
understanding of the SAR of the ophiobolin family against CLL cells. Ophiobolin U was unstable and 
therefore not applied in any bioassay, but the remaining ten ophiobolins were tested for their cytotoxic 
activity towards CLL cells. Ophiobolin A, B, C, and K showed the strongest effects with LC50 values 
between 1 and 8 nM (results compiled in Table 1 and Figure 12a). Testing of normal lung fibroblasts 
revealed that ophiobolin A and B displayed cytotoxic effects at 10 nM concentration indicating a slight 
difference in bio-activity for CLL cells in comparison to healthy fibroblasts. Ophiobolin C and K 
displayed no effect towards normal lung fibroblasts in concentrations up to 10 nM (Figure S17). 
Interestingly, 3-anhydroophiobolin A, 3-anhydro-6-epiophiobolin A, 6-epiophiobolin G, ophiobolin H, 
6-epiophiobolin K, and 6-epiophiobolin N exhibited low or no activity towards CLL cells. In fact,  
6-epiophiobolin K targeted CLL cell viability only when applied at a 100-fold higher concentration 
than ophiobolin K (Figure 12b). Ophiobolin-treated cells were further stained with PE-labelled 
Annexin-V and 7-AAD, or antibodies for activated caspase-3 prior to flow cytometric analyses. 
Thereby, apoptosis was identified as the mode of killing of CLL cells as demonstrated recently for 
chaetoglobosin A [15]. 
Table 1. Apoptosis inducing activity (LC50 [nM]) of the 10 ophiobolins towards CLL cells. 
Compound LC50
Ophiobolin A 1 nM 
3-anhydro-ophiobolin A Inactive 
3-anhydro-6-epiophiobolin A Inactive 
Ophiobolin B 2 nM 
Ophiobolin C 8 nM 
6-epiophiobolin G Inactive 
Ophiobolin H Inactive 
Ophiobolin K 4 nM 
6-epiophiobolin K Inactive 
6-epiophiobolin H Inactive 
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Figure 12. Effects of different ophiobolins on CLL cell viability. (a) CLL cells cultured in 
HS-5 conditioned media were treated for 24 h with increasing concentrations of ophiobolin A, 
ophiobolin B, ophiobolin C, ophiobolin K, and 6-epiophiobolin K, and cell viability was 
analyzed by CellTiter-Glo® assay measuring each data point as duplicate. Relative cell 
viability compared to DMSO control (0.1%) is depicted as mean values +SD of 3 independent 
CLL samples; (b) As 6-epiophiobolin K treatment did not decrease cell viability in the 
concentration range tested in (a), CLL cells were treated with up to 900 nM of 6-epiophiobolin 
K, and cell viability was determined and compared to the active ophiobolin B. 
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The results displayed in Table 1 and Figure 12a indicates that presence of a hydroxy group at C3 
and an aldehyde at C21 is crucial for the activity of the ophiobolins. Our findings are thus in agreement 
with previous studies that have shown that these two groups covalently bind to calmodulin [51,52]. 
None of the 6-epiophiobolins tested were active against the CLL cells. To earn a broader understanding of 
the importance of this small steric change at C6, 3D-modeling of ophiobolin K (blue) and 6-epiophiobolin 
K (red) were done to give a visual representation of their lowest energy conformations (Figure 13). 
Figure 13. Modulated 3D structures of ophiobolin K (blue) and 6-epiophiobolin K (red) in 
their lowest energy conformations overlaid. H6 protons are marked in ophiobolin K (cyan) 
and 6-epiophiobolin K (orange). The chain extending from C14 in ring C is not displayed to 
get a better clarity of the structures (the cut-off point is marked with *). 
 
The difference in conformation between ophiobolin K and 6-epiophiobolin K involves a flipping of 
the eight-membered ring that result in a change of position of the C21 aldehyde from one to the other 
side of the plane observed in the figure. This conformational change is likely preventing the binding of 
calmodulin by the C21 aldehyde due to steric hindrance, resulting in the lack of activity for  
6-epiophiobolin K contrasting ophiobolin K.  
3. Experimental 
3.1. General 
The fungal strains used are from the IBT culture collection at Department of Systems Biology, 
Technical University of Denmark. The LC-MS analyses were performed on a maXis quadrupole time 
of flight (qTOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) with an electrospray 
ionization (ESI) ion source. The maXis was calibrated using sodium formate automatically infused 
prior to each analytical run, providing a mass accuracy of below 1 ppm. The mass spectrometer was 
linked to an Ultimate 3000 UHPLC system (Dionex, Sunnyvale, CA, USA) with DAD. Separation was 
achieved on a Kinetex C18, 2.6 µm, 2.1 × 100 mm column (Phenomenex, Torrance, CA, USA) with a 
flow of 0.4 mL min−1 at 40 °C using a linear gradient 10% acetonitrile (ACN) in Milli-Q water (MQ) 
with 20 µM formic acid (FA) going to 100% ACN in 10 min. All compounds were isolated by bio-
guided fractionation started by flash chromatography of the crude extracts, fractionated with an Isolera 
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One automated flash system (Biotage, Uppsala, Sweden). The isolation of compounds were performed 
by a semi-preparative Gilson HPLC system (Middleton, WI, USA) with a 215 Liquid Handler,  
819 Injection Module and a 172 DAD and fully controlled with Trilution LC software or on a Waters 
600 chromatograph (Milford, MA, USA) attached to a Waters 600 DAD. One-dimensional and  
two-dimensional NMR experiments were acquired using standard pulse sequences on a 800 MHz 
Bruker Avance spectrometer with a 5 mm TCI cryoprobe at the Danish Instrument Centre for NMR 
Spectroscopy of Biological Macromolecules at Carlsberg Laboratory, alternatively on a 500 MHz 
Varian Unity Inova (Palo Alto, CA, USA) equipped with a HCP probe or a 400 MHz Bruker Avance 
III equipped a BBO Prodigy cryoprobe NMR spectrometers. 
3.2. Micro Extraction for Initial Screen 
Two hundred and eighty nine (289) fungal extracts were prepared from cultivation of 137 fungal 
strains (Table S1). All extracts were prepared in accordance with the micro-extraction method 
developed by Smedsgaard [22]. Five plugs were collected across the colony. The samples were 
subsequently extracted using (3:2:1 v/v/v) methanol (MeOH), dichloromethane (DCM) and ethyl 
acetate (EtOAc) with 0.5% FA. 
3.3. Cultivation and Extraction 
The seven extracts described here were P. pulvillorum (IBT 22393), P. brasilianum (IBT 22244),  
P. decumbens (IBT 11843), P. cluniae (IBT 21051), Aspergillus sp. (Emericella-like state, IBT 22838), 
F. compactum (IBT 9034), and a new species in Aspergillus section Usti (IBT 18591). Each fungus 
was cultivated on 50 plates (media are listed in supplementary) for 8 days at 25 °C in the dark with the 
exceptions of P. brasilianum. P. brasilianum (IBT 22244), A. insuetus (IBT 28266), and A. calidoustus 
(IBT 25726) were cultivated on 200 agar plates with Yeast Extract Sucrose (YES) for 14 days (except 
A. calidoustus that was incubated for 7 days) at 25 °C in the dark. All the fungi were extracted 
separately with EtOAc containing 1% FA. Unwanted carbohydrates from the media as well as fatty 
acids were removed from the four large extract (P. brasilianum, the new species in Aspergillus section 
Usti, A. insuetus, and A. calidoustus) by liquid-liquid extraction with water/MeOH and heptane, 
respectively leaving the crude extracts. 
3.4. Bioassay-Guided Fractionation 
The crude extract of P. decumbens, P. pulvillorum, P. cluniae, Aspergillus sp. (Emericella-like 
state), and F. compactum were fractionated on a RP C18 (25 g, 33 mL) column flash column with at 
gradient of: 15%–100% ACN in 20 min and flow rate 25 mL/min. No further fractionations were  
done with the bioactive flash fraction from the P. cluniae extract. Penicillic acid was purified from  
the bioactive flash fraction from the P. pulvillorum extract by semi-preparative HPLC LunaII C18  
(250 × 10 mm, 5 µm) column with at gradient of: 15%–100% ACN in 20 min and flow rate 5 mL/min. 
ACN and MQ were added 20 mM FA. 
Penicillic acid: White solid; UV (ACN) λmax: 227 nm; HRMS m/z 170.0573 (M+ calculated for 
C8H10O4, m/z 170.0574; 0.5 ppm). 
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3.4.1. E-SPE 
P. brasilianum, P. decumbens, Aspergillus sp. (Emericella-like state), and F. compactum extracts 
were prefractionated analytical in accordance with the E-SPE method developed by Månsson et al. [21] 
with SAX, MAX, and SCX ion-exchanger SPE columns though without the Sephadex LH-20 column. 
Additionally two normal phase (amino and diol) columns were add to the setup. For each extract, 5 mg 
was loaded on both the amino column (100 mg, 1 mL) and the diol column (100 mg, 1 mL). The 
compounds were eluted by 2 column volume (CV) heptane, 2 CV DCM, 2 CV DCM/EtOAc (1:1),  
2 CV EtOAc, 2 CV EtOAc/MeOH, 2 CV MeOH, 4 CV ACN, 2 CV ACN/MQ + 2% FA (75:25), 2 CV 
ACN/MQ + 2% FA (50:50), 2 CV ACN/MQ + 2% FA (25:75), 2 CV ACN/MQ + 2% FA (10:90). No 
further fractionations were done with the bioactive flash fraction from the P. decumbens extract. 
The bioactive C18 flash fraction from the Aspergillus sp. (Emericella-like state) extract was loaded 
on the amino column (10 g, 15 mL) and eluted by 2 CV heptane, 2 CV DCM, 2 CV DCM/EtOAc 
(1:1), 2 CV EtOAc, 2 CV EtOAc/MeOH, 2 CV MeOH, 4 CV ACN, 2 CV ACN/MQ + 2% FA(75:25), 
2 CV ACN/MQ + 2% FA (50:50), 2 CV ACN/MQ + 2% FA (25:75), 2 CV ACN/MQ + 2% FA 
(10:90). Emestrin A (1.1 mg) was finally isolated by preparative HPLC on a LunaII C18 (250 × 10 mm, 
5 µm) column with at gradient of: 50%–100% ACN in 20 min and flow rate 5 mL/min. ACN and MQ 
were added 50 ppm trifluoroacetic acid (TFA). 
Emestrin A: White solid; [α]589.3nm: +22°; UV (ACN) λmax: 230 (sh), 267 (sh), 285 (sh); HRMS m/z 
598.0713 (M+ calculated for C27H22N2O10S2, m/z 598.0711; 0.4 ppm).  
The bioactive C18 flash fraction from the F. compactum extract was loaded on a diol column (10 g, 
15 mL) and eluted by 2 CV heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV DCM/EtOAc (1:1), 
2 CV EtoAc, 2 CV EtOAc/MeOH, 2 CV MeOH, 2 CV MeOH/ACN (1:1) and 2 CV ACN. Neosolaniol 
monoacetate was isolated with semi-preparative HPLC on a Luna II, C18, 5 µm, 10 × 250 mm column 
with 30%–70% ACN in 20 min and flow rate 5 mL/min. ACN and MQ were added 20 mM FA. 
Neosolaniol monoacetate: White solid; HRMS m/z 424.1728 (M+ calculated for C21H28O9, m/z 
424.1728; 0 ppm). 
The crude extract of P. brasilianum was loaded on a SAX column (100 g, 132 mL) and washed by 
1 CV 70% MeOH in MQ (pH 11) and 1 CV 100% MeOH (pH 7) giving the SAX-1 fraction. 
Subsequently eluted by 2 CV 100% MeOH (pH 2) giving the SAX-2 fraction. Viridicatumtoxin was 
isolated (27.5 mg) from SAX-2 on a RP C18 column with at gradient of: 30%–100% ACN in 60 min 
and flow rate 40 mL/min. ACN and MQ were added 50 ppm TFA. 
Viridicatumtoxin: Yellow solid; UV (ACN) λmax: 238, 286, 435 nm; HRMS m/z 565.1942 (M+ 
calculated for C30H31NO10, m/z 565.1942; 0 ppm). 
3.4.2. Ophiobolins 
The crude extract of a new species in Aspergillus section Usti (IBT 18591) was fractionated on a 
RP C18 (25 g, 33 mL) flash column with at gradient of: 15%–100% ACN in 20 min and flow rate  
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25 mL/min. Subsequently the active fraction was loaded on a diol flash column and eluted with 2 CV 
heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV EtOAc, 2 CV MeOH. Ophiobolin K and  
6-epiophiobolin K were isolated from the active fraction by semi-preparative HPLC on a Luna II, C18, 
5 µm, 10 × 250 mm column by 70%–100% ACN in 25 min and flow rate 5 mL/min. 
Ophiobolin K: White solid; [α]589.3nm: +161°; UV (ACN) λmax: 241 nm; HRMS m/z 384.2658 (M+ 
calculated for C25H36O3, m/z 384.2659; 0.3 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
6-Epiophiobolin K: White solid; [α]589.3nm: +53°; UV (ACN) λmax: 239 nm; HRMS m/z 384.2658 (M+ 
calculated for C25H36O3, m/z 384.2659; 0.3 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
The crude extract of A. insuetus (IBT 28266) was loaded on a diol flash column and eluted with  
2 × 2 CV heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV EtOAc, 2 CV MeOH. The active 
fraction was then loaded on a RP C18 flash column with at gradient of: 80%–100% ACN in  
45 min and flow rate 40 mL/min. Ophiobolin U, ophiobolin H and 6-epiophiobolin N were isolated 
from the active fraction by semi-preparative HPLC on a Gemini, C6-Ph, 5 µm, 10 × 250 mm column. 
Ophiobolin U was purified by 55%–70% ACN in 25 min and flow rate 5 mL/min. Ophiobolin H and  
6-epiophiobolin N were purified by 50% ACN isocratic in 15 min, then 50–60 min ACN in 15 min, 
and then up to 100% ACN in 5 min. ACN and MQ were added 50 ppm TFA. 
Ophiobolin U: White solid; [α]589.3nm: +3°; UV (ACN) λmax: 242 nm; HRMS m/z 386.2813 (M+ 
calculated for C25H38O3, m/z 386.2816; 0.5 ppm); 1H-NMR (800 MHz, CDCl3): δ 0.91 (2H, d, 6.7, H23), 
0.99 s (3H, s, H22), 1.03 (1H, m, H1a), 1.26 (3H, s, H20), 1.38 (2H, m, H12), 1.55 (1H, m, H10), 1.58 
(1H, m, H1b), 1.58 (1H, m, H13a), 1.74 (3H, s, H24), 1.78 (1H, m, H13b), 1.82 (3H, s, H25), 1.87 
(1H, dd, 4.1, 15.1, H4a), 2.09 (1H, m, H14), 2.24 (1H, m, H9a), 2.30 (1H, m, H2), 2.68 (1H, dd, 7.9, 
15.1, H4b), 2.72 (1H, m, H15), 2.89 (1H, dd, 8.5, 12.5, H9b), 3.02 d (1H, d, 9.6, H6), 4.91 (1H, dd, 
4.7, 7.9, H5), 5.21 (1H, t, 10.0, H16), 6.00 (1H, m, H18), 6.03 (1H, m, H17), 6.94 t (1H, d, 8.5, H8), 
9.26 (1H, s, H21); 13C-NMR (200 MHz, CDCl3): δ 18.3 (C24), 18.6 (C22), 20.6 (C23), 25.6 (C9), 26.3 
(C20), 26.7 (C13), 26.7 (C25), 35.2 (C1), 35.9 (C15), 42.0 (C12), 44.1 (C11), 47.4 (C14), 50.5 (C6), 
51.0 (C2), 53.4 (C4), 54.0 (C10), 73.1 (C5), 81.9 (C3), 120.2 (C18), 122.3 (C17), 135.9 (C19), 137.7 
(C16), 142.1 (C7), 164.1 (C8), 198.1 (C21). Full dataset is found in Table S10. 
Ophiobolin H: White solid; [α]589.3nm: +60°; UV (ACN) λmax: 241 nm; HRMS m/z 386.2817 (M+ calculated 
for C25H38O3, m/z 386.2816; −0.5 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
6-Epiophiobolin N: White solid; [α]589.3nm: +10°; UV (ACN) λmax: 232 nm; HRMS m/z 368.2711 (M+ 
calculated for C25H36O2, m/z 368.2710; −0.2 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
The crude extract of A. calidoustus (IBT 25726) was loaded on a diol flash column and eluted with  
2 CV heptane, 2 CV heptanes/DCM (1:1), 2 CV DCM, 2 CV EtOAc, 2 CV MeOH. Ophiobolin C and  
6-epiophiobolin G were isolated from the active fraction by semi-preparative HPLC on a Luna II, C18, 
5 µm, 10 × 250 mm column. Ophiobolin C was purified by 80% ACN in MQ and 6-epiophiobolin G 
was purified by 80% MeOH in MQ both isocratic with a flow rate of 5 mL/min. 
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Ophiobolin C: White solid; [α]589.3nm: +298°; UV (ACN) λmax: 240 nm; HRMS m/z 386.2813 (M+ 
calculated for C25H38O3, m/z 386.2816; 0.7 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
6-Epiophiobolin G: White solid; [α]589.3nm: +127°; UV (ACN) λmax: 234 nm; HRMS m/z 366.2553 (M+ 
calculated for C25H34O2, m/z 366.2554; 0.1 ppm); 13C- and 1H-NMR: see Tables S8 and S9, respectively. 
3.5. CLL Cells, Cell Viability and Apoptosis Assays 
Whole blood samples were obtained from patients that matched the standard diagnostic criteria for 
CLL after informed consent in accordance with the Declaration of Helsinki. All studies performed 
were approved by the ethics committee of the University of Ulm. Peripheral blood mononuclear cells 
(PBMC) were isolated by Ficoll density gradient and consisted of at least 80% CD5+CD19+ leukemic 
cells as determined by flow cytometry. For the initial screen, cocultures of HS-5 stromal cells and CLL 
cells were established as previously described [53]. For retesting of bio-active substances, CLL cells 
were cultured in conditioned media of HS-5 cells, which was harvested after 3–4 days of culture and 
80% confluency and depleted of HS-5 cells and debris by centrifugation. CLL cells were seeded in 
duplicates at a density of 3 × 105 cells/well in opaque-walled 96-well plates. Fractions or pure 
compounds were added in different concentrations and incubated for 24 h. 0.1% DMSO was used as a 
negative control. Cell viability was assessed using CellTiter-Glo® assay (Promega, Madison, WI, 
USA) according to manufacturer’s protocol. Luminescence signals were recorded using a Mithras 
LB940 plate reader (Berthold Technologies, Bad Wildbad, Germany). Background signals of medium 
were subtracted from each well as described by Knudsen et al. [15]. 
Apoptotic cell death was detected by flow cytometry using Annexin V-phycoerythrin (PE) and  
7-aminoactinomycin (7-AAD) staining kit (BD Biosciences, Heidelberg, Germany) as described by 
Seiffert et al. [12]. To confirm apoptosis induction, staining for active caspase 3 was performed  
after fixation and permeabilization of cells using BD Cytofix/CytopermTM solution as described by  
the manufacturer by using PE-conjugated anti-active caspase 3 antibodies (clone C92-605, BD 
Biosciences). All flow cytometry analyses were carried out using a FACSCanto II flow cytometer 
equipped with FACSDiva software (BD Biosciences). 
4. Conclusions 
In conclusion, our combined bio-guided and dereplication based discovery approach has proven to 
be effective for fast dereplication and discovery of bioactive fungal natural products that target CLL 
cells. Comparative testing of active extracts on CLL cells as well as healthy cells identified compounds 
with general and selective bioactivity. The ophiobolin family showed high activity for CLL cells. The 
known ophiobolins A, B, C and K induced apoptosis in CLL cells with LC50 values of 1, 2, 8, and 4 nM, 
respectively with a lower bioactivity for healthy fibroblasts. The high activities for CLL cells were 
found only in ophiobolins with a hydroxy group at C3, an aldehyde at C21, and A/B-cis ring structure. 
In the remaining six bioactive extracts, the compounds responsible for the activity were tentatively 
identified by dereplication, and the activities towards CLL cells were verified by testing the pure 
compounds. The six active compounds, penicillic acid, viridicatumtoxin, calbistrin A, brefeldin A, 
emestrin A, and neosolaniol monoacetate, were all known and generally cytotoxic. In order to identify 
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substances that are of therapeutic value for cancer cells, selective active substances need to be retested 
on a large cohort of cancer and healthy cells. In general, cytotoxic compounds are only suitable as  
anti-cancer pharmaceuticals if they selectively target the cancer cells and not healthy cells, or at least 
have a higher impact on the tumor cells. Activity optimization is well exemplified with these studies 
demonstrating the great potential of looking into the chemistry of closely related species to obtain 
more analogue compounds of a promising scaffold. 
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